Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial

Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial

BackgroundRetreatment with anti-EGFR monoclonal antibodies is a promising strategy in patients with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC) who achieved benefit from previous anti-EGFR exposure upon exclusion of mutations in RAS/BRAF genes according to circulating tumor DNA (ctDN...

Full description

Bibliographic Details
Main Authors: Marco Maria Germani, Guglielmo Vetere, Mirella Giordano, Paolo Ciracì, Iolanda Capone, Elena Tamborini, Elena Conca, Adele Busico, Filippo Pietrantonio, Vittoria Matilde Piva, Alessandra Boccaccino, Francesca Simionato, Martina Bortolot, Paolo Manca, Sara Lonardi, Veronica Conca, Beatrice Borelli, Martina Carullo, Marzia Del Re, Gabriella Fontanini, Daniele Rossini, Chiara Cremolini
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
mCRC
anti-EGFR
retreatment
ctDNA
liquid biopsy
next generation sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1307545/full

Similar Items

Similar Items